{"url_path":"/sec/idya/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1676725/0001193125-26-251399-index.html","accession_number":"0001193125-26-251399","cik":"0001676725","ticker":"IDYA","issuer_name":"IDEAYA Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1676725/0001193125-26-251399-index.html","primary_entity_key":"0001676725","primary_entity_name":"IDEAYA Biosciences, Inc."},"word_count":130,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 1, 2026, IDEAYA Biosciences, Inc. (the “Company”) presented an investor presentation in connection with the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}